US2006052334A1PendingUtilityA1

Sequential therapy comprising a 20(S)-camptothecian and a pyrimidine base analog

51
Assignee: RUBINFELD JOSEPHPriority: Feb 21, 2002Filed: Sep 23, 2005Published: Mar 9, 2006
Est. expiryFeb 21, 2022(expired)· nominal 20-yr term from priority
Inventors:Joseph RubinfeldKarl MettingerJohn Francis LyonsLawrence Romel
A61K 31/4745A61K 31/513A61K 31/7072
51
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method is provided for treating a patient having a disease associated with undesirable or uncontrolled cell proliferation, the method comprising: administering to the patient a 20(S)-camptothecin for a period of time during which a pyrimidine base analog is not being administered to the patient; and administering a pyrimidine base analog to the patient.

Claims

exact text as granted — not AI-modified
1 . A method for treating a patient having a disease associated with undesirable or uncontrolled cell proliferation, the method comprising: 
 administering to the patient a 20(S)-camptothecin for a period of time during which a pyrimidine base analog is not being administered to the patient; and    administering a pyrimidine base analog to the patient.    
   
   
       2 . A method according to  claim 1  wherein the 20(S)-camptothecin is administered at least 1 day before the pyrimidine base analog is administered.  
   
   
       3 . A method according to  claim 1  wherein the 20(S)-camptothecin is administered at least 2 days before the pyrimidine base analog is administered.  
   
   
       4 . A method according to  claim 1  wherein the 20(S)-camptothecin is administered at least 3 days before the pyrimidine base analog is administered.  
   
   
       5 . A method according to  claim 1  wherein the 20(S)-camptothecin is administered at least 4 days before the pyrimidine base analog is administered.  
   
   
       6 . A method according to  claim 1  wherein the 20(S)-camptothecin is administered at least 5 days before the pyrimidine base analog is administered.  
   
   
       7 . A method according to  claim 1  wherein the 20(S)-camptothecin is administered between 1 and 90 days before the pyrimidine base analog is administered.  
   
   
       8 . A method according to  claim 1  wherein the 20(S)-camptothecin is administered between 2 and 90 days before the pyrimidine base analog is administered.  
   
   
       9 . A method according to  claim 1  wherein the 20(S)-camptothecin is administered between 3 and 90 days before the pyrimidine base analog is administered.  
   
   
       10 . A method according to  claim 1  wherein the 20(S)-camptothecin is administered between 4 and 90 days before the pyrimidine base analog is administered.  
   
   
       11 . A method according to  claim 1  wherein the 20(S)-camptothecin is administered between 5 and 90 days before the pyrimidine base analog is administered.  
   
   
       12 . A method according to  claim 1  wherein the 20(S)-camptothecin is administered at least 1 day after the pyrimidine base analog is administered.  
   
   
       13 . A method according to  claim 1  wherein the 20(S)-camptothecin is administered at least 2 days after the pyrimidine base analog is administered.  
   
   
       14 . A method according to  claim 1  wherein the 20(S)-camptothecin is administered at least 3 days after the pyrimidine base analog is administered.  
   
   
       15 . A method according to  claim 1  wherein the 20(S)-camptothecin is administered at least 4 days after the pyrimidine base analog is administered.  
   
   
       16 . A method according to  claim 1  wherein the 20(S)-camptothecin is administered at least 5 days after the pyrimidine base analog is administered.  
   
   
       17 . A method according to  claim 1  wherein the 20(S)-camptothecin is administered between 1 and 90 days before or after the pyrimidine base analog is administered and is also administered within 1 day of when the pyrimidine base analog is administered.  
   
   
       18 . A method according to  claim 1  wherein the 20(S)-camptothecin is administered between 2 and 90 days before or after the pyrimidine base analog is administered and is also administered within 2 days of when the pyrimidine base analog is administered.  
   
   
       19 . A method according to  claim 1  wherein the 20(S)-camptothecin is administered between 3 and 90 days before or after the pyrimidine base analog is administered and is also administered within 3 days of when the pyrimidine base analog is administered.  
   
   
       20 . A method according to  claim 1  wherein the 20(S)-camptothecin is administered between 4 and 90 days before or after the pyrimidine base analog is administered and is also administered within 4 days of when the pyrimidine base analog is administered.  
   
   
       21 . A method according to  claim 1  pancreatic cancer wherein the pyrimidine base analog is a fluorinated analog of a pyrimidine base.  
   
   
       22 . A method according to  claim 1  pancreatic cancer wherein the pyrimidine base analog is a fluorinated analog of uracil.  
   
   
       23 . A method according to  claim 1  wherein the 20(S)-camptothecin is 9-nitro-20(S)-camptothecin.  
   
   
       24 . A method according to  claim 1  wherein the disease associated with undesirable or uncontrolled cell proliferation is cancer.  
   
   
       25 . A method according to  claim 1  wherein the cancer is selected from the group consisting of acute myelogenous leukemia, cholangiocarcinoma, chronic myelogenous leukemia, lymphoma, melanoma, multiple myeloma, osteosarcoma, gastric sarcoma, glioma, bladder, breast, cervical, colorectal, lung, ovarian, pancreatic, prostrate, and stomach cancer.  
   
   
       26 . A method according to  claim 1  wherein the disease associated with undesirable or uncontrolled cell proliferation is pancreatic cancer.  
   
   
       27 . A method for treating a patient having a disease associated with undesirable or uncontrolled cell proliferation, the method comprising: 
 administering to the patient a 20(S)-camptothecin for a period of time during which a pyrimidine base analog is not present in a pharmacologically active form in the patient's body; and administering a pyrimidine base analog to the patient.    
   
   
       28 . A method according to  claim 27  wherein the 20(S)-camptothecin is administered at least 1 day before the pharmacologically active pyrimidine base analog is present in the patient's body.  
   
   
       29 . A method according to  claim 27  wherein the 20(S)-camptothecin is administered at least 2 days before the pharmacologically active pyrimidine base analog is present in the patient's body.  
   
   
       30 . A method according to  claim 27  wherein the 20(S)-camptothecin is administered at least 3 days before the pharmacologically active pyrimidine base analog is present in the patient's body.  
   
   
       31 . A method according to  claim 27  wherein the 20(S)-camptothecin is administered at least 4 days before the pharmacologically active pyrimidine base analog is present in the patient's body.  
   
   
       32 . A method according to  claim 27  wherein the 20(S)-camptothecin is administered at least 5 days before the pharmacologically active pyrimidine base analog is present in the patient's body.  
   
   
       33 . A method according to  claim 27  wherein the 20(S)-camptothecin is administered between 1 and 90 days before the pharmacologically active pyrimidine base analog is present in the patient's body.  
   
   
       34 . A method according to  claim 27  wherein the 20(S)-camptothecin is administered between 2 and 90 days before the pharmacologically active pyrimidine base analog is present in the patient's body.  
   
   
       35 . A method according to  claim 27  wherein the 20(S)-camptothecin is administered between 3 and 90 days before the pharmacologically active pyrimidine base analog is present in the patient's body.  
   
   
       36 . A method according to  claim 27  wherein the 20(S)-camptothecin is administered between 4 and 90 days before the period when the pharmacologically active pyrimidine base analog is present in the patient's body.  
   
   
       37 . A method according to  claim 27  wherein the 20(S)-camptothecin is administered between 5 and 90 days before the pharmacologically active pyrimidine base analog is present in the patient's body.  
   
   
       38 . A method according to  claim 27  wherein the 20(S)-camptothecin is administered at least 1 day after the pharmacologically active pyrimidine base analog is no longer present in the patient's body.  
   
   
       39 . A method according to  claim 27  wherein the 20(S)-camptothecin is administered at least 2 days after the pharmacologically active pyrimidine base analog is no longer present in an active form in the patient's body.  
   
   
       40 . A method according to  claim 27  wherein the 20(S)-camptothecin is administered at least 3 days after the pharmacologically active pyrimidine base analog is no longer present in an active form in the patient's body.  
   
   
       41 . A method according to  claim 27  wherein the 20(S)-camptothecin is administered at least 4 days after the pharmacologically active pyrimidine base analog is no longer present in an active form in the patient's body.  
   
   
       42 . A method according to  claim 27  wherein the 20(S)-camptothecin is administered at least 5 days after the pharmacologically active pyrimidine base analog is no longer present in an active form in the patient's body.  
   
   
       43 . A method according to  claim 27  wherein the 20(S)-camptothecin is administered between 1 and 90 days before or after the pharmacologically active pyrimidine base analog is present in the patient's body and is also administered within 1 day of when the pharmacologically active pyrimidine base analog is present in the patient's body.  
   
   
       44 . A method according to  claim 27  wherein the 20(S)-camptothecin is administered between 2 and 90 days before or after the pharmacologically active pyrimidine base analog is present in the patient's body and is also administered within 2 days of when the pharmacologically active pyrimidine base analog is present in the patient's body.  
   
   
       45 . A method according to  claim 27  wherein the 20(S)-camptothecin is administered between 3 and 90 days before or after the pharmacologically active pyrimidine base analog is present in the patient's body and is also administered within 3 days of when the pharmacologically active pyrimidine base analog is present in the patient's body.  
   
   
       46 . A method according to  claim 27  wherein the 20(S)-camptothecin is administered between 4 and 90 days before or after the time when the pharmacologically active pyrimidine base analog is present in the patient's body and is also administered within 4 days of when the pharmacologically active pyrimidine base analog is present in the patient's body.  
   
   
       47 . A method according to  claim 27  wherein the 20(S)-camptothecin is administered between 5 and 90 days before or after the time when the pharmacologically active pyrimidine base analog is present in the patient's body and is also administered within 5 days of when the pharmacologically active pyrimidine base analog is present in the patient's body.  
   
   
       48 . A method according to  claim 27  wherein the pyrimidine base analog is a fluorinated analog of a pyrimidine base.  
   
   
       49 . A method according to  claim 27  wherein the pyrimidine base analog is a fluorinated analog of uracil.  
   
   
       50 . A method according to  claim 27  wherein the 20(S)-camptothecin is 9-nitro-20(S)-camptothecin.  
   
   
       51 . A method according to  claim 27  wherein the disease associated with undesirable or uncontrolled cell proliferation is cancer.  
   
   
       52 . A method according to  claim 27  wherein the cancer is selected from the group consisting of acute myelogenous leukemia, cholangiocarcinoma, chronic myelogenous leukemia, lymphoma, melanoma, multiple myelorna, osteosarcoma, gastric sarcoma, glioma, bladder, breast, cervical, colorectal, lung, ovarian, pancreatic, prostrate, and stomach cancer.  
   
   
       53 . A method according to  claim 27  wherein the disease associated with undesirable or uncontrolled cell proliferation is pancreatic cancer.

Join the waitlist — get patent alerts

Track US2006052334A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.